Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

eyecare

- PMLiVE

Relief for Shire as FDA clears NPS’ Natpara

Drug was a key interest as part of NPS takeover

Shire Basingstoke

Shire signs deal to buy NPS for $5.2bn

Firm hopes to boost its presence in rare disease sector

Shire Basingstoke

Shire drawn into Luxembourg tax haven exposé

Firm is one of 340 companies identified in report by ICIJ

- PMLiVE

AbbVie is not looking at another big acquisition, says CEO

Unlikely to consider another deal on the scale of failed Shire merger

- PMLiVE

AbbVie and Shire bring merger plans to a close

Blames tax changes in the US

- PMLiVE

AbbVie board recommends dropping Shire deal

Tells stakeholders to vote against merger in light of new rules on corporate tax

- PMLiVE

AbbVie rethinks Shire merger in light of US tax crackdown

Follows action to discourage 'inversion deals' aimed at reducing corporate tax rates

Shire Basingstoke

Shire reaches $56.5m US marketing malpractice settlement

Justice Department agreement covers activities for drugs including Adderall

- PMLiVE

It’s on: Shire and AbbVie agree £32bn takeover

Companies agree deal that is set to cut US pharma company’s corporate tax bill

- PMLiVE

AbbVie coaxes Shire into discussions with sweetened offer

Raises takeover bid to $53bn

- PMLiVE

AbbVie raises Shire bid to £30bn

Latest offer is company’s fourth attempt at takeover

Shire Basingstoke

Shire spells out why AbbVie takeover is a bad idea

Talks up its growth prospects as an independent company

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links